Association of Antiviral Prophylaxis and Rituximab Use with Post-transplant Lymphoproliferative Disorders (PTLD): A Nationwide Cohort Study

Scheduled for Tuesday, March 9, 2020, from 11:00 AM ET to 12:00 PM ET • Hosted by the AST Infectious Disease Community of Practice (IDCOP)

"Association of Antiviral Prophylaxis and Rituximab Use with Post-transplant Lymphoproliferative Disorders (PTLD): A Nationwide Cohort Study" (doi.org/10.1111/ajt.16423)

In this article:
The role of antiviral prophylaxis or rituximab therapy for prevention of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the incidence, presentation, and outcome of histologically proven PTLD. We included 4765 patients with a follow‐up duration of 23 807 person‐years (py). Fifty‐seven PTLD cases were identified; 39 (68%) were EBV positive (EBV+ PTLD)... However, none of the patients (0/191) who received a rituximab‐containing induction treatment experienced PTLD, but 57 of 4574 patients without rituximab induction developed PTLD. In an adjusted restricted mean survival time model, PTLD‐free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients receiving rituximab as induction treatment. This study provides novel data on the association of rituximab induction and reduced risk for PTLD.

Speaker:
Laura Walti, MD; Inselspital, Bern University Hospital; Bern, Switzerland

Moderator:
Upton Allen; MBBS, MSc, FAAP; SickKids, University of Toronto; Toronto, Canada

AST/AJT Journal Clubs are free, but registration is required.

Register

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.